A Randomized, Open-Label, Three-Way Crossover Study to Evaluate the Effect on 24-hour, Intragastric pH Following Daily Oral Dose Administration of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40-mg Capsules and Rabeprazole (Aciphex) 20-mg Tablets to H. Pylori-Negative Healthy Subjects in a 5-day Treatment Regimen.

Trial Profile

A Randomized, Open-Label, Three-Way Crossover Study to Evaluate the Effect on 24-hour, Intragastric pH Following Daily Oral Dose Administration of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40-mg Capsules and Rabeprazole (Aciphex) 20-mg Tablets to H. Pylori-Negative Healthy Subjects in a 5-day Treatment Regimen.

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Oct 2013

At a glance

  • Drugs Esomeprazole; Rabeprazole
  • Indications Bleeding ulcer; Duodenal ulcer; Dyspepsia; Gastric ulcer; Gastro-oesophageal reflux; Helicobacter infections; NSAID-induced ulcer; Peptic ulcer; Reflux oesophagitis; Zollinger-Ellison syndrome
  • Focus Pharmacodynamics
  • Most Recent Events

    • 04 Nov 2010 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
    • 04 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Nov 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top